Phase II evaluation of a combination of @entity1138 , XXXX , and @entity900 in advanced @entity1149 .

@entity1 @entity137 @entity390 @entity882 @entity1138 @entity900 @entity1149 @entity3794 @entity391 @entity1897 @entity1891 @entity1431 @entity27810 @entity99
The combination treatment of @entity1138 (M), @entity1891 (V), and @entity900 (P) ( @entity27810 ) in 63 @entity1 with advanced @entity1149 ( @entity1149 ) were evaluated for their potential synergistic @entity137 . The overall response rate was 43% (27/63); in the 54 eligible and evaluable @entity1 , the response rate was 50% (27/54). Responses were observed in all cell types and disease sites. Cell type; performance status of 0, 1, or 2; sex; and age younger or older than 60 years did not significantly influence the response rate. However, @entity1 with prior radiation had significantly more treatment failure than those without. The dose-limiting side effects in these 54 @entity1 were myelosuppression (40%), @entity3794 (9%), @entity1897 (6%), and intractable @entity390 and @entity391 (4%). The degree of @entity1431 (P less than 0.01) but not of @entity882 increased significantly in @entity1 who had received prior radiotherapy. One @entity1 died of marked @entity882 and one of fulminant @entity99 . @entity1 who responded lived significantly longer than those who did not (P less than 0.004). A majority of the responders (82%) also achieved symptomatic palliation. With appropriate dose modification and supportive care, @entity27810 was tolerable. Further trials with this regimen or a modified version are worth consideration.
